Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 3/20 | 0.33 |
| ▸ | GRIN3B known ✓ | O60391 | 3/20 | 0.33 |
| ▸ | GRIN1 known ✓ | Q05586 | 3/20 | 0.33 |
| ▸ | GRIN2A known ✓ | Q12879 | 3/20 | 0.33 |
| ▸ | GRIN2B known ✓ | Q13224 | 3/20 | 0.33 |
| ▸ | GRIN2C known ✓ | Q14957 | 3/20 | 0.33 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 3/20 | 0.33 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.36 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29213093 | 0.98 | MAPT (0.38) | MAPTLMNAPOLBTHRBBLM | |
| Phosphine SCHEMBL25171299 | 0.97 | SLC22A2 (0.37) | MAPTLMNAPOLBTHRBBLM | |
| SCHEMBL3334426 | 0.97 | SLC22A2 (0.37) | MAPTLMNAPOLBTHRBBLM | |
| SCHEMBL498011 | 0.97 | SLC22A2 (0.37) | MAPTLMNAPOLBTHRBBLM | |
| Ammonia Solution, Strong SCHEMBL28147130 | 0.95 | SLC22A2 (0.36) | MAPTLMNAPOLBTHRBBLM | |
| Phosphoric Acid SCHEMBL27711128 | 0.85 | GAA (0.43) | SLC22A2SLC47A1 | |
| Formamide SCHEMBL27718948 | 0.85 | SLC22A2 (0.34) | MAPTLMNAPOLBTHRBBLM | |
| Formic Acid SCHEMBL28177125 | 0.85 | THRB (0.31) | THRBSLC22A2SLC47A1 | |
| SCHEMBL28239328 | 0.82 | — | — | |
| Biphenyl SCHEMBL261710 | 0.80 | OPRK1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101389594-A | Process for the preparation of adamantanamines | HEXAL AG (DE) | 2009-03-18 | — | — | CN | disclosed |
| CN-101102996-A | Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride | TEVA PHARM FINE CHEMICALS SRL (IT) | 2008-01-09 | — | — | CN | disclosed |
| CN-101102994-A | Polymorphs of memantine hydrochloride | TEVA PHARM FINE CHEMICALS SRL (IT) | 2008-01-09 | — | — | CN | disclosed |
| CN-1878550-A | Methods for identifying improved, non-sedating alpha-2 agonists | ALLERGAN INC (US) | 2006-12-13 | — | — | CN | disclosed |
| EP-1701700-A1 | COMPOSITIONS COMPRISING MEMANTINE AND POLYANIONIC POLYMERS FOR ADMINISTRATION TO THE EYE | Allergan, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1663207-A2 | NOVEL METHODS FOR IDENTIFYING IMPROVED, NON-SEDATING a-2 AGON ISTS | Allergan, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005067891-A1 | COMPOSITIONS COMPROSING MEMANTINE AND POLYANIONIC POLYMERS FOR ADMINISTRATION TO THE EYE | ALLERGAN, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005034849-A2 | METHODS FOR IDENTIFYING IMPROVED, NON-SEDATING ALPHA-2 AGONISTS | ALLERGAN, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1455837-A1 | PHARMACEUTICAL CONJUGATES WITH ENHANCED PHARMACOKINETIC CHARACTERISTICS | Allergan, Inc. (US) | 2004-09-15 | — | — | EP | disclosed |
| CN-1125033-C | Synthesis of memantine hydrochloride | GUANGZHOU INST CHEMISTRY CAS (CN) | 2003-10-22 | — | — | CN | disclosed |
| WO-2003051400-A1 | PHARMACEUTICAL CONJUGATES WITH ENHANCED PHARMACOKINETIC CHARACTERISTICS | ALLERGAN, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| CN-1335299-A | Synthesis of memantine hydrochloride | GUANGZHOU INST OF CHEMISTRY AC (CN) | 2002-02-13 | — | — | CN | disclosed |